Regeneron Pharmaceuticals Inc (REGN)

Name: Regeneron Pharmaceuticals Inc (REGN) — تاریخچه صورتهای مالی
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

تاریخچه درآمد، سود و جریان نقد از صورت‌های مالی رسمی.

Health Care · وال‌استریت (آمریکا) · آخرین به‌روزرسانی: 2026-08-16

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

شاخص‌های کلیدی

ارزش بازار: $83 billion
درآمد (سال مالی منتهی به 2025-12-31): $14.3B
سود خالص: $4.5B
حاشیه سود ناخالص: 85.4%
حاشیه سود خالص: 31.4%

نمودارهای تعاملی و صورت‌های مالی کامل ← مدل ارزش‌گذاری (DCF) ←

صورت سود و زیان سالانه

صورت سود و زیان	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
مجموع درآمد	$15.5B	$14.3B	$14.2B	$13.1B	$12.2B	$16.1B	$8.5B	$7.9B	$6.7B	$5.9B	$4.9B	$4.1B	$2.8B	$2.1B	$1.4B	$446M	$459M	$379M	$238M	$125M	$63M
سود ناخالص	$13.2B	$12.2B	$12.2B	$12.2B	$10.5B	$13.3B	$7.1B	$7.1B	$6.3B	$5.5B	$4.6B	$3.7B	$2.6B	$1.9B	$1.3B	$442M	$457M	$363M	$238M	$125M	$41M
حاشیه سود ناخالص %	84.9%	85.4%	86.1%	93.3%	86.0%	83.0%	84.0%	90.0%	93.5%	93.2%	93.8%	90.4%	92.7%	92.6%	93.9%	99.1%	99.5%	95.8%	99.6%	100.0%	64.2%
سود عملیاتی (EBIT)	$4.0B	$3.6B	$4.0B	$4.0B	$5.4B	$8.9B	$3.6B	$2.2B	$2.5B	$2.1B	$1.3B	$1.3B	$838M	$760M	$458M	($205M)	($97M)	($74M)	($90M)	($114M)	($107M)
حاشیه سود عملیاتی %	25.6%	24.9%	28.1%	30.9%	44.2%	55.7%	42.1%	28.1%	37.8%	35.4%	27.4%	30.5%	29.7%	36.1%	33.2%	-46.0%	-21.2%	-19.5%	-37.7%	-91.5%	-169.1%
سود خالص	$4.3B	$4.5B	$4.4B	$4.0B	$4.3B	$8.1B	$3.5B	$2.1B	$2.4B	$1.2B	$896M	$636M	$348M	$424M	$750M	($222M)	($104M)	($68M)	($83M)	($106M)	($102M)
حاشیه سود خالص %	27.9%	31.4%	31.1%	30.1%	35.6%	50.2%	41.3%	26.9%	36.4%	20.4%	18.4%	15.5%	12.3%	20.2%	54.4%	-49.7%	-22.8%	-17.9%	-34.7%	-84.5%	-161.3%
EBITDA	—	$5.8B	$5.3B	$4.0B	$5.3B	$9.7B	$4.1B	$2.4B	$2.7B	$2.2B	$1.4B	$1.3B	$891M	$801M	$495M	($174M)	($78M)	($55M)	($79M)	($82M)	($77M)
سود هر سهم (EPS)	$40.46	$41.48	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.29	$10.34	$7.70	$5.52	$3.07	$3.81	$6.50	$-2.45	$-1.26	$-0.85	$-1.05	$-1.59	$-1.77
سهام منتشرشده (میلیون)	—	109M	115M	114M	114M	112M	115M	115M	115M	116M	116M	115M	113M	111M	115M	91M	83M	80M	79M	66M	58M

منبع: گزارش‌های عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.

ترازنامه‌ها، جریان‌های نقدی، داده‌های فصلی و نسبت‌های مالی کامل در نمایشگر تعاملی REGN در دسترس است. /companies/us/REGN

اطلاعات این وب‌سایت صرفاً برای اهداف آموزشی و اطلاع‌رسانی است و توصیه سرمایه‌گذاری نیست. هیچ هدف قیمتی یا توصیه‌ای منتشر نمی‌شود.

English version →همه سهام

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.